The hippo signaling pathway: implications for heart regeneration and disease by Dominic P Del Re
Del Re Clinical and Translational Medicine 2014, 3:27
http://www.clintransmed.com/content/3/1/27REVIEW Open AccessThe hippo signaling pathway: implications for
heart regeneration and disease
Dominic P Del ReAbstract
Control of cell number and organ size is critical for appropriate development and tissue homeostasis. Studies in
both Drosophila and mammals have established the Hippo signaling pathway as an important modulator of organ
size and tumorigenesis. Upon activation, this kinase cascade modulates gene expression through the phosphorylation
and inhibition of transcription co-activators that are involved in cell proliferation, differentiation, growth and apoptosis.
Hippo signaling serves to limit organ size and suppress malignancies, and has been implicated in tissue regeneration
following injury. These outcomes highlight the important role that Hippo signaling plays in regulating both physiologic
and pathologic processes. In this review, an overview of the signaling pathway will be discussed as well as recent work
that has investigated its role in cardiac development, regeneration and disease.
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Myocardial infarction (MI), or insufficient blood flow to the
heart muscle, promotes thedeath and loss of cardiomyocytes
resulting in heart damage and impaired cardiacfunction.
While patient survival following MI has improved, the prog-
nosis is typicallypoor and can eventually progress to heart
failure, a leading cause of morbidity andmortality [1]. Be-
cause mature cardiomyocytes have a limited capacity to re-
enter the cellcycle and proliferate [2,3], the ability of the
adult heart to regenerate is similarlyrestricted and cannot
adequately replace lost cardiomyocytes. The Hippo signa-
lingpathway is evolutionarily conserved from flies to mam-
mals and has emerged as animportant regulator of both cell
survival and proliferation [4,5]. Importantly, this cascadealso
appears critical for proper mammalian heart development
and the post-natal responseto cardiac stress and injury[6-8].
It is therefore plausible to hypothesize that Hipposignaling
could be targeted to promote heart regeneration after MI
and heart injury. Thisreview will provide an overview of the
Hippo pathway and examine its role in cardiacdevelopment,
disease and regeneration.Correspondence: delredo@njms.rutgers.edu
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Hippo signaling in Drosophila
Determining how multicellular organisms attain and
maintain appropriate organ size has plagued researchers
and remains a major quest. Studies employing genetic mo-
saic screens in Drosophila melanogaster shed new light on
this question and identified the core components of what
is now known as the Hippo signaling pathway, appropri-
ately named after Hippo kinase. Mutant flies genetically
deficient for a functional Hippo (Hpo) [1-5], Salvador
(Sav) [6,7] or Warts (Wts) [8,9] exhibited similar pheno-
types consisting of robust tissue overgrowth, enhanced cell
proliferation and suppressed apoptosis. These shared phe-
notypes suggested the involvement of each in a common
signaling cascade that regulated organ size, which was
subsequently demonstrated through additional genetic
and protein interaction studies. Integral work revealed
that Hippo (a serine/threonine kinase) interacts with
Salvador (a WW-repeat protein and scaffold) and pro-
motes the phosphorylation of both Salvador and Warts
kinase [1]. A fourth core component, Mats (Mob as tumor
suppressor) is also phosphorylated by Hippo and was
found to play an important role in this cascade by inter-
acting with Warts, which may further facilitate Warts acti-
vation [10,11]. These seminal studies demonstrated how
the association and phosphorylation between core compo-
nents promoted Hippo pathway activation.en Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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critical link between the Hippo cascade and gene expres-
sion. Using a yeast two-hybrid approach with Warts as
bait, they were able to identify the transcription co-
activator Yorkie (Yki) as a downstream target of Hippo
signaling [12]. Subsequent work demonstrated that Yorkie
is a direct substrate of Warts and that Yorkie promotes
cell proliferation and growth. Importantly, inactivation of
Yorkie was sufficient to prevent the overgrowth phenotype
observed in Hippo pathway mutants, indicating that
Yorkie is the major downstream effector of the pathway
[12,13]. Yorkie itself lacks the ability to bind DNA directly
and therefore influences gene expression through its inter-
action with the transcription factor Scalloped (Sd) [14-17].
Scalloped was demonstrated to mediate Yorkie-triggered
overgrowth; however, overexpression of Scalloped alone
did not elicit overgrowth, suggesting that Yorkie regula-
tion is the critical factor for determining gene expression
downstream of Hippo signaling [14].
Hippo signaling in mammals
There is high conservation of Hippo signaling compo-
nents between Drosophila and mammals. Similar to the
fly, mammalian Hippo signaling involves the activation of
a conserved kinase cascade that ultimately phosphorylates
the transcription co-activator Yap (Yes-associated protein)
and its paralog TAZ (transcriptional co-activator with a
PDZ-binding motif; both are orthologs of Drosophila Yki),
thereby regulating downstream gene expression, cell pro-
liferation and organ growth (for excellent reviews, see
[18-22]). The core components of the mammalian Hippo
pathway include the serine/threonine kinases Mst1/2
(mammalian sterile 20-like kinase; ortholog of Drosophila
Hpo) and Lats1/2 (large tumor suppressor; ortholog of
Drosophila Wts), as well as the adapter proteins Salvador
(Sav1; also referred to as WW45) and Mob1 (Mps one
binder; ortholog of Drosophila Mats)[23]. Analogous to
Hippo signaling in the fly, Mst1/2 associates with and
phosphorylates Sav1, which further promotes Mst1/2 acti-
vation. Once activated, Mst1/2 directly phosphorylates
and activates Lats1/2[24]. Mst1/2 can also phosphorylate
Mob1, which may further promote pathway activation
through a currently undefined mechanism. Interestingly,
Hippo signaling appears to have a high degree of evolu-
tionary conservation from flies to humans as mammalian
orthologs exist for each fly counterpart and generally
function in a similar manner. However, it should be noted
that recent work has demonstrated a clear divergence
between select upstream pathway components (e.g.,
Drosophila Fat and Expanded, see below) and may explain
why regulation of core Hippo signaling by these orthologs
appears inconsistent between flies and mammals [25].
Furthermore, Yorkie/Yap transcriptional differences have
been observed between flies and mammalian cell typeshighlighting differences in Hippo signaling outputs be-
tween species [26].
Regulation of gene expression by the Hippo
pathway
Like many other established signal transduction pathways,
Hippo signaling regulates a transcriptional program. The
identification of Yorkie as a direct substrate of Warts pro-
vided the important link between the Hippo core compo-
nents and gene expression [12,13,27]. As mentioned above,
Yorkie does not bind DNA and partners with Scalloped to
mediate gene expression, cell proliferation and survival
[15-17]. Several gene targets of Hippo signaling have been
identified in Drosophila, including cyclin E, diap1, and the
microRNA bantam, which may modulate cell proliferation
and survival [1,12,14,28,29]. Similarly, the Yorkie orthologs
Yap/TAZ cannot bind DNA directly and modulate gene ex-
pression through transcription factor interaction. Perhaps
the most established are the TEAD1-4 (TEA domain family
member) transcription factors (orthologs of Drosophila Sd),
which have been shown to mediate many of the cellular ef-
fects of activated Yap/TAZ [17,30-44]. In addition to tran-
scriptional partnering with TEADs, Yap/TAZ have the
ability to co-activate or co-repress other known transcrip-
tion factors including p73 [45], ErbB-4 [46], Runx [47,48],
FoxO1 [49], Tbx5 [50] and Smads [51-53]; however their re-
spective roles in Hippo signaling are not clear.
Yap has been the focus of intense research since it was
discovered to be the link between Hippo signaling and
gene expression. Yap contains five potential Lats phos-
phorylation sites (HXRXXS) and mutation of one of these
sites, a serine to alanine substitution at residue 127, was
shown to attenuate Yap phosphorylation by Lats2 and
modulate its subcellular distribution from cytosolic to nu-
clear prevalence [13,27,54,55]. Serine 127 phosphorylation
promotes 14-3-3 binding and Yap cytosolic retention and
led to a decrease in Yap-TEAD interaction, although this
modification did not directly alter Yap-TEAD binding
[13]. Additional phosphorylation of Yap at serine 381
serves as a phosphodegron and promotes its proteosomal
degradation [56]. Interestingly, recent work has shown
that PKA-mediated phosphorylation of Lats2 promotes its
kinase activity toward Yap, but is selective for serine 381,
thereby enhancing Yap degradation [57]. These findings
suggest that distinct signaling may bias Lats-mediated
phosphorylation and subsequent regulation of Yap.
Yap activity is also regulated by multiple upstream
signaling pathways that are independent of Hippo signaling.
Yap was originally discovered as a WW-domain-containing
protein that interacted with Yes, a member of the Src fam-
ily of tyrosine kinases [58]. Subsequent work has shown
that Yap is phosphorylated by Yes/Src and that this is re-
quired to enable Yap modulation of Runx2-mediated tran-
scription [48]. Yap/TAZ also display extensive crosstalk
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and increased phosphorylation of Yap/TAZ has been shown
to promote their interaction with β-catenin, increasing cyto-
solic retention of β-catenin, and thereby negatively regulat-
ing Wnt/β-catenin signaling [59]. Additionally, inhibition of
Hippo and activation of Yap caused increased β-catenin-
mediated gene expression in the heart, and β-catenin was
found to be required for the activated Yap phenotype [60].
Similar findings were observed using a constitutively active
Yap mutant – namely that active Yap promotes β-catenin
target gene expression both directly and indirectly (through
activation of IGF-1 signaling) and that β-catenin is a critical
mediator of Yap function [61]. These findings suggest that
Yap is a positive regulator of the Wnt/β-catenin pathway.
Conversely, studies have also demonstrated that Wnt/β-
catenin signaling regulates the function of Yap/TAZ. Acti-
vation of Wnt causes stabilization of Yap through its tar-
get tribbles homolog 2 (TRIB2) [62]. Wnt can also
prevent degradation of TAZ by preventing the phosphor-
ylation of β-catenin, which serves as a bridge that links
TAZ to its ubiquitin ligase β-TrCP [63]. Recently pub-
lished work has further clarified the underlying mechan-
ism by demonstrating that Yap/TAZ are integral
components of the β-catenin destruction complex and
that Wnt activation triggers the nuclear aggregation of
both β-catenin and Yap/TAZ [64]. Additional reports have
implicated the involvement of JNK in regulating Yap activ-
ity either directly through JNK phosphorylation of Yap
[65] or indirectly by promoting the interaction of Lats
with Ajuba family proteins thereby limiting the Lats-Yap
inhibitory interaction [66]. Taken altogether, these studies
highlight the crosstalk surrounding Yap/TAZ and suggest
they are key nodes of signaling transduction.
Upstream modulators of Hippo signaling in
Drosophila
As the importance of Hippo signaling becomes increas-
ingly apparent, significant efforts have been made to clarify
the proximal signaling responsible for pathway modulation.
In Drosophila, a number of potential upstream compo-
nents have been identified as important pathway regula-
tors. Genetic screens identified the FERM domain family
members Merlin (Mer) and Expanded (Ex). Mutations in
either of these genes led to an attenuation of Hippo signal-
ing in flies [67]. Interestingly, Expanded was shown to
negatively regulate Yorkie directly through a protein-
protein interaction, which led to cytosolic sequestration
and increased Yorkie degradation [68,69]. The mechanism
responsible for linking Merlin to the core Hippo kinase
cassette remained elusive until elegant work from Pan and
colleagues revealed a potential mechanism. Their study
found that membrane-associated Merlin binds and recruits
Warts to the plasma membrane. Here, Warts is phosphor-
ylated by an independent Hippo/Salvador complex, therebypromoting pathway activation. Of note, this work was
unique in demonstrating spatial compartmentalization of
this signaling pathway [24]. Additional studies have impli-
cated Kibra, a protein known to interact with both Merlin
and Expanded, as a potential regulator of Hippo signaling.
Indeed, loss of Kibra function appears to phenocopy mer
and ex mutants, while Kibra overexpression caused in-
creased phosphorylation of Hippo, Warts and Yorkie
[70-72]. Fat, an atypical protocadherin, has also been iden-
tified as an upstream regulator, and possible membrane
receptor, of Hippo signaling in the fly [73-77]. Fat mutants
(loss-of-function) displayed overgrowth phenotypes simi-
lar to those of Hippo pathway loss-of-function mutants, as
well as dysregulation of Hippo phosphorylation and
Yorkie target gene expression [73-75]. Furthermore, Fat
modulated protein levels and proper localization of Ex-
panded, identifying a potential mechanism that links Fat
to Hippo. Daschous, another transmembrane cadherin,
also regulates Hippo signaling through its interaction with
Fat and Zyxin, ultimately modulating Warts protein levels
[78]. Crumbs, a known cell polarity factor in Drosophila,
has also been implicated in Hippo signaling [53,79,80].
Loss of Crumbs caused mislocalization of Expanded and
inhibition of Hippo activation, leading to hyperactivation
of Yorkie and increased tissue growth [81,82]. It has also
been demonstrated that Hippo is phosphorylated in its ac-
tivation loop by Tao-1, another member of the sterile 20-
like kinase family. Phosphorylation of Hippo by Tao-1
promoted the activation of core Hippo components and
led to restrained Yorkie function [83,84]. Recent work
from Wehr et al. employed a genome-wide RNAi screen
in Drosophila and identified the salt-inducible kinases,
Sik2 and Sik3, as negative regulators of Hippo signaling
[85]. The Siks were found to disrupt Hippo/Warts com-
plex formation through phosphorylation of Salvador, lead-
ing to increased Yap activation. As these kinases may be
sensitive to nutrient sensing, they could provide a link be-
tween extracellular cues and growth through the Hippo
pathway. Yet another kinase, homeodomain-interacting
protein kinase 2 (HIPK2) has been demonstrated to regu-
late Hippo pathway activity. However, HIPK2 does not
appear to modulate upstream Hippo members, but in-
stead directly phosphorylates and activates Yorkie to pro-
mote increased tissue growth [86,87]. Given the intense
interest in Hippo signaling, this burgeoning list of path-
way components continues to expand. In this regard, for
a more in-depth discussion of additional regulators of the
Hippo pathway, the reader is referred to these excellent
reviews [21,88-92].
Upstream modulators of mammalian Hippo
signaling
Although many Drosophila Hippo pathway components
have mammalian orthologs, and although many of these
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their fly counterparts, great care must be exercised when
investigating Hippo signaling in mammalian systems as
it most likely will prove to be more complex and
nuanced. In fact, clear differences between flies and
mammals with regard to Hippo signaling have been
demonstrated [25,26,93]. Nonetheless, substantial effort
has been directed toward elucidating the proximal regu-
lators of mammalian Hippo signaling in recent years and
significant progress has been made on this front.
RASSF1A (Ras association domain family 1A) is a tumor
suppressor and scaffold protein that has been shown to
interact with Mst1/2 and Sav1 to promote activation of
Hippo signaling [94,95]. RASSF1A causes increased
Mst1/2 autophosphorylation, at least in part through
suppression of Mst1/2 dephosphorylation by PP2A [96],
thereby promoting Mst1/2 activation and subsequent
apoptosis [97,98]. It should be noted that the Drosophila
ortholog of RASSF1A (dRASSF) was demonstrated to
prevent Hippo activation [93], a reminder of the poten-
tial differences between flies and mammals. Studies in-
volving the tumor suppressor NF2 (Neurofibromin 2;
ortholog of Merlin) have demonstrated its role in regu-
lating mammalian Hippo signaling. Targeted deletion of
the Nf2 gene in the mouse liver (albumin-Cre driver spe-
cific for hepatocytes and biliary cells) led to increased
Yap activation, increased cell proliferation, increased
liver size and eventual hepatocellular carcinoma (HCC)
[99,100]. Interestingly, this NF2 KO phenotype was com-
pletely prevented in mice that were also haplo-deficient
for Yap, indicating that augmented Yap activity is re-
sponsible for this pathology [99]. On the other hand,
treatment with an EGFR (epidermal growth factor recep-
tor) inhibitor also prevented the overgrowth caused by
Nf2 deletion, suggesting that multiple pathways down-
stream of NF2 may be altered and contribute to HCC
[100]. Loss of NF2 function in the dorsal telencephalon of
the murine brain also elicited increased Yap/TAZ activation
and increased cell proliferation/expansion leading to devel-
opmental defects [101]. While these results implicate a role
for NF2 in regulating Hippo signaling in two distinct tissues,
additional work has demonstrated a similar anti-proliferative
but non-Hippo-related effect. Specifically, NF2 was found to
translocate to the nucleus where it inhibited the E3 ligase
DCAF1 to suppress cell proliferation independent of Hippo
signaling [102]. Taken together, RASSF1A and NF2 appear
to be positive modulators that promote mammalian Hippo
signaling in multiple tissue types.
The ability to sense and transduce extracellular signals
and/or cues from the surrounding environment into the
cell is a hallmark of traditional signaling pathways. Along
these lines, work from Guan and colleagues demonstrated
that cell density regulates the activation status of Hippo
signaling [13]. Cell-to-cell contact, long known to causeinhibition of proliferation, was linked to the inactivation
of Yap. Importantly, this work demonstrated the involve-
ment of the Hippo pathway in regulating cell proliferation
in response to the cell density signal. Further studies re-
vealed that α-catenin is an important mediator of the cell
density signal and a direct regulator of Yap phosphoryl-
ation and degradation in epithelial stem cells [39]. In a
similar vein, Kim et al. reported that E-cadherin regulates
Yap exclusion from the nucleus in a cell-density-dependent
context [103]. Yap inhibition and cytosolic retention caused
by cell-cell contact was mediated by E-cadherin, and forced
Yap expression was able to overcome the anti-proliferative
effect of E-cadherin. For excellent reviews regarding Hippo
regulation by cell-cell contact and cell polarity see [91,104].
In a landmark study, the Guan group was the first to
demonstrate that extracellular receptors, in this case
GPCRs (G-protein-coupled receptors), could modulate
Hippo signaling [105]. Ligands that preferentially couple
to Gα12/13 (e.g., LPA, S1P), and to a lesser extent Gαq,
were shown to inhibit Hippo signaling and promote Yap
activation. Conversely, ligands that preferentially activate
Gαs (e.g., epinephrine) stimulated Hippo signaling and
inhibited Yap activity. Follow-up work described similar
findings for PARs (protease-activated receptors), a subset
of GPCRs that is stimulated by the endogenous ligand
thrombin [106]. Further independent work confirmed
that the extracellular diffusible signals LPA and S1P are
indeed potent activators of Yap [107]. Interestingly, these
ligands appear to act through the actin cytoskeleton and
the small G-protein RhoA, as the signaling cascade is
sensitive to actin disruption and inhibition of RhoA, and
regulate the function of Lats kinases to control Yap ac-
tivity [105,107,108]. Further investigation into the con-
nection between cytoskeletal integrity and Lats identified
a role for PKA (cAMP-dependent protein kinase) in
the regulation of Hippo signaling. cAMP/PKA were
shown to cause Yap/TAZ phosphorylation and inhibition
through a process requiring actin polymerization and
RhoA [57,108]. Kim et al. also demonstrated direct
phosphorylation and activation of Lats2 by PKA. This
modification appeared to bias Lats2 kinase activity to-
ward inhibitory phosphorylation of Yap at serine 381 but
not serine 127 [57]. In addition to GPCR-dependent
modulation of Hippo signaling, two compelling studies
demonstrated a role for receptor tyrosine kinases (RTKs)
in regulating this cascade. Fan et al. demonstrated that
activation of the EGF receptor in mammary cells caused
the activation of Yap [109]. Mechanistically, the authors
demonstrated that this was mediated by PI3K and
PDK1, which are activated downstream of EGF receptor
engagement, but did not require AKT. Instead, PDK1 as-
sociates with Salvador to disrupt the core Hippo signal-
ing components, leading to Lats inhibition and Yap
activation. A similar finding was reported by Reddy and
Figure 1 A schematic representation of mammalian Hippo signaling. The core components of the Hippo pathway in mammals consist of
Mst1/2, Lats1/2, Salvador (Sav1) and Mob1. Active Lats1/2 phosphorylates and inhibits Yap/TAZ. Yap phosphorylation on Serine 127 results in
14-3-3 binding and cytosolic retention (right side) while Serine 381 phosphorylation leads to proteosomal degradation (left side). Nuclear Yap/
TAZ regulate gene expression resulting in proliferation, growth and survival. Yap/TAZ association with several identified transcription factors is
shown. Arrows and blunt lines indicate activation and inhibition, respectively.
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MAPK activation and phosphorylation of the Ajuba fam-
ily protein WTIP (Wilms tumor protein 1-interacting
protein). The fly homolog of WTIP, Jub, was also phos-
phorylated by MAPK, causing it to bind to Salvador and
Warts, inhibiting Warts and eliciting Yorkie activation
(see Figure 1).
Additional groundbreaking studies from the Piccolo
lab have shown that extracellular matrix (ECM) stiffness
and mechanotransduction systems can also modulate
the activity of Yap/TAZ [111]. This work demonstrated
that Yap/TAZ are a critical link between ECM rigidity
and altered gene expression, which is known to affect
cell growth, differentiation and proliferation. The cell’s
ability to spread and the amount of mechanical stress to
which it is subjected were identified as key regulators of
Yap/TAZ nuclear localization and transcriptional activ-
ity. The underlying mechanism was found to be medi-
ated by RhoA and actomyosin tension; however, Mst/
Lats kinases appeared to be dispensable. Further work
using a siRNA screen of F-actin-associated proteins
identified and subsequently confirmed Cofilin, CapZ and
Gelsolin as important inhibitors of Yap/TAZ in cells ex-
periencing low mechanical stress [112]. Taken altogether,
regulation of mammalian Hippo signaling is complexand likely incorporates multiple upstream inputs to de-
termine intensity and duration of signal activation. Fur-
thermore, it is likely that regulation and function of this
pathway are cell- and tissue-type-specific and additional
investigation is therefore needed.
Hippo signaling and heart development
The mammalian heart develops from mesodermal tis-
sues, first forming a heart tube, which then loops and
gives rise to atrial and ventricular components and an
outflow tract. These complex processes require finely or-
chestrated spatial-temporal signaling events between
multiple cell types to give rise to a normal, healthy heart
[113]. Tbx5 is a transcription factor and one of several
known regulators of embryonic heart development
[114]. Importantly, Tbx5 can be co-activated by Yap/
TAZ, indicating the possible involvement of Hippo sig-
naling in early stage heart development [50].
Recent studies have begun to further examine the role
of Hippo in mammalian cardiogenesis. A mouse model
harboring embryonic deletion of Sav1, Mst1/2 or Lats2
in the heart revealed the importance of these Hippo
components for proper organ development [60]. All
knockout lines displayed a similar phenotype and
showed hyperproliferation of cardiomyocytes with
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myocyte number. These mice also died prior to birth.
Mechanistically, there was significant upregulation of
Wnt target gene expression, which was rescued by cross-
ing the Hippo mutant mice with those deficient for β-
catenin. These findings suggest that Hippo restrains car-
diomyocyte proliferation and heart size by inhibiting
Wnt signaling and point to the importance of Hippo sig-
naling during cardiogenesis. In a complimentary ap-
proach, two additional groups utilized genetically altered
mice that harbored embryonic deletion of Yap in the
heart to interrogate the function of endogenous Yap dur-
ing heart development [61,115]. Importantly, two differ-
ent promoters were used to drive cardiomyocyte-specific
Cre recombinase expression; however, similar results
were observed between the two lines including a de-
crease in cardiomyocyte proliferation, a decrease in pro-
growth and proliferative gene expression (the former via
Wnt/β-catenin and the latter via TEAD), and embryonic
lethality between E10.5-12.5. Taken together, these find-
ings demonstrate the critical involvement of Hippo sig-
naling during cardiogenesis and suggest that a balance
of Yap activity is required for proper heart formation
(see Table 1 for overview of Hippo-related mouse
models and cardiac phenotypes).
Hippo signaling in cardiac regeneration
Embryonic heart growth occurs mainly through prolifer-
ation of cardiomyocytes, whereas shortly after birthTable 1 Overview of Hippo-related mouse models
Mouse line Cardiac phenotype
Mst1 Tg (αMHC) Dilated cardiomyopathy, increased apopto
Premature death.
DN-Mst1 Tg (αMHC) Normal cardiac function. Protection agains
Lats2 Tg (αMHC) Baseline cardiac dysfunction. Reduced hear
DN-Lats2 Tg (αMHC) Cardiac hypertrophy with normal cardiac fu
Sav1 cKO (Nkx2.5-cre) Embryonic lethal. Cardiomegaly, thickened
Mst1/2 cKO (Nkx2.5-cre) Embryonic lethal. Enlarged heart.
Lats1/2 cKO (Nkx2.5-cre) Embryonic lethal. Enlarged heart.
Yap Tg (αMHC) Enlarged heart with increased proliferation
Yap Tg (βMHC) Enlarged heart with Increased proliferation
Yap Tg (αMHC; ROSA26fs-rtTA;
TRE-Yap)
Normal cardiac function. Increased prolifera
no change in apoptosis.
Yap cKO (Nkx2.5-cre) Embryonic lethal. Reduced heart size, redu
Yap cKO (Tnnt2-cre) Embryonic lethal. Reduced heart size, redu
Yap cKO (αMHC-cre) Dilated cardiomyopathy, increased apopto
premature death. Worsened outcome after
Sav1 cKO (αMHC-MCM) Normal cardiac function. Increased prolifera
Protected against MI.
Lats1/2 cKO (αMHC-MCM) Normal cardiac function. Increased prolifera
Protected against MI.
A summary of Hippo pathway gain- and loss-of-function mouse models with corresthese cells experience a dramatic reduction in their abil-
ity to divide. Thus, further organ growth is almost exclu-
sively mediated through the enlargement of existing
cardiomyocytes. Around this same time, the ability of the
mammalian heart to regenerate following injury drastically
declines. It should be noted, however, that low-level car-
diomyocyte turnover seems to occur throughout adult
mammalian life [116,117] and approaches aimed at
exploiting this phenomenon are an active area of cardio-
vascular research. This is in contrast to the zebrafish,
which is able to regenerate up to 20% of its cardiac mass
following myocardial resection, even during adulthood
[118]. Because the loss of cardiomyocytes in response
to injury is a major contributor to impaired function
and heart failure, it is fundamental to understand the
mechanisms that regulate proliferation and consequently
regeneration of adult mammalian cardiomyocytes. Yap has
been demonstrated to promote the self-renewal and
“stemness” of embryonic stem cells [119], satellite muscle
cells [120] and liver cells [121], while suppressing or even
reversing their differentiation, indicating that Yap could
potentially be targeted to manipulate precursor cell fate
and perhaps modify regenerative capacity.
Several studies have demonstrated the ability of Yap to
promote proliferation of neonatal rat cardiomyocytes. By
using adenoviral overexpression systems, these gain-of-
function approaches upregulated active Yap and elicited
increases in Ki-67-positive, phosphorylated histone H3-
positive, and BrdU-positive cardiomyocytes in cultureYap activity References
sis and no compensatory hypertrophy. ND [129]
t I/R and MI. ND [129,130]
t size. ND [135]
nction. Protection against I/R. ND [135]
walls and increased proliferation. Increased [60]
ND [60]
ND [60]
. Increased cardiac regeneration. Increased [123]
. Increased [115]
tion. Protection against MI with Increased [124]
ced proliferation. Reduced [61,115]
ced proliferation. Reduced [115]
sis, increased fibrosis and
MI (het).
Reduced [122,123]
tion and heart regeneration. Increased [125]
tion and heart regeneration. Increased [125]
ponding cardiac phenotypes and effects on Yap activity. ND = not determined.
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also caused increased cardiomyocyte proliferation, indi-
cating that this observation is not limited or specific to
neonatal cells [115,123,124]. Similarly, conditional dele-
tion of Sav1 in the adult mouse heart, which causes
increased Yap activation, also triggered increased cardio-
myocyte proliferation [125], providing further evidence
that Hippo signaling restrains adult cardiomyocyte re-
newal. Recent work has demonstrated that neonatal
mouse hearts have a regenerative capacity similar to zeb-
rafish during the first 7 days after birth (P1-7); however,
following P7 this capacity for heart renewal declines dra-
matically [126]. To determine whether Hippo signaling
regulates neonatal heart regeneration, Yap transgenic
mice were generated. Increased cardiac Yap expression
was able to protect against cardiomyocyte loss, fibrosis
and scarring after chronic myocardial infarction (MI) in
mice beginning at P7. Conversely, cardiac-specific dele-
tion of Yap ablated the neonatal regenerative capacity
observed in wild-type mice following MI. Yap CKO mice
had larger scar areas while wild-type neonates appeared
normal [123], suggesting that Yap is a critical mediator
of heart regeneration shortly after birth. Additional stud-
ies utilized inducible cardiac Sav1 and Lats1/2 CKO
mice to test whether these Hippo pathway components
could also influence the regenerative capacity of the
mammalian heart [125]. Conditional deletion of Sav1 or
Lats1/2 in neonatal mice was shown to promote heart
repair and extend the regenerative potential following
cardiac resection at P8. Furthermore, Hippo deficiency
led to increased cardiomyocyte proliferation and myocar-
dial protection in response to MI either at P8 or in 8-
week-old adult mice. These Sav1 CKO mice also had
improved cardiac function and smaller scars after MI
compared to wild-type controls. In sum, these studies in-
dicate that Hippo signaling is an important modulator of
cardiomyocyte proliferation and myocardial regeneration
in response to injury.
Hippo signaling in heart disease
Mst1 was first cloned and characterized nearly 20 years
ago and was later identified as a Hippo ortholog and a
core component of the mammalian Hippo signaling
pathway [127]. Mst1 is activated during apoptosis of
cancer cell lines [128] and cardiomyocytes [129] and,
importantly, contributes to their programmed cell death.
Myocardial Mst1 transgene expression driven by the
cardiomyocyte-specific αMHC promoter led to a pro-
found cardiac phenotype in mice [129]. Mst1 transgenic
(Tg) mice developed severe dilated cardiomyopathy at a
young age and died prematurely due to heart failure.
These Tg mice had elevated caspase activation and car-
diomyocyte apoptosis, which contributed to ventricular
wall thinning and a decline in cardiac function. On theother hand, using the same approach to express a
kinase-inactive (K59R) DN-Mst1 in the heart inhibited
endogenous Mst1 activity and afforded cardioprotection
[129]. During ischemia and reperfusion (I/R), which sim-
ulates acute coronary occlusion and subsequent restor-
ation of blood flow, Mst1 is activated and contributes to
cardiomyocyte apoptosis. Indeed, DN-Mst1 Tg mice
showed significantly fewer TUNEL-positive cardiomyo-
cytes and significantly reduced scar formation following
I/R [129]. Wild-type non-transgenic (NTg) and DN-Mst1
Tg mice were also subjected to chronic MI. DN-Mst1 Tg
mice had less apoptosis, reduced fibrosis, attenuation of
left ventricle dilation and improved cardiac function com-
pared to controls [130]. Autophagy, an established
adaptive mechanism that can protect the heart during
stress [131], is also regulated by Mst1 in the adult mouse
heart. Recent work demonstrated that Mst1-mediated
phosphorylation of Beclin-1 promotes the association of
Beclin-1 with Bcl-2 and thereby inhibits cardiomyocyte
autophagy [132]. This inhibitory mechanism translates to
increased myocardial injury in response to prolonged is-
chemia. Another recently identified target of Mst1 is the
pro-survival Bcl-2 family member Bcl-xL. During I/R,
Mst1 was found to translocate to mitochondria and phos-
phorylate Bcl-xL, causing its dissociation from Bax and
leading to Bax activation and cardiomyocyte apoptosis
[133]. These findings provide novel mechanisms to ex-
plain how Mst1 elicits detrimental outcomes in the heart.
Work in pancreatic beta cells has also demonstrated a
deleterious role of Mst1 through the promotion of beta
cell apoptosis and dysfunction that could contribute to in-
sulin resistance [134]. Together these findings suggest that
Mst1 could be a valid therapeutic target not only for the
treatment of heart disease, but diabetes as well.
Similar to Mst1, increased expression of Lats2 pro-
motes, while expression of DN-Lats2 attenuates, apop-
tosis of cultured cardiomyocytes [135]. Interestingly,
Lats2 Tg mice had increased myocardial fibrosis and de-
pressed cardiac function, while no significant difference
in cardiomyocyte apoptosis was observed under basal
conditions. Transgenic expression of DN-Lats2 was used
to inhibit endogenous Lats2 in the mouse heart. In re-
sponse to pressure overload stress (an experimental
model of hypertension), DN-Lats2 Tg mice were pro-
tected against cardiomyocyte apoptosis and showed an
enhanced hypertrophic response, i.e., individual cardio-
myocyte enlargement leading to greater overall heart
mass [135]. DN-Lats2 Tg mice were also protected
against I/R injury and had significantly lower levels of
cardiomyocyte apoptosis and scar formation after I/R,
which was mediated through increased Yap activation
[49]. Taken together, these findings implicate Mst1 and
Lats2 as critical mediators of myocardial injury and dys-
function following both acute and prolonged stress.
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malian Hippo signaling [94-98]. In the heart, two separate
groups utilizing independently generated RASSF1A KO
mouse lines reported very similar observations [136,137].
RASSF1A KO mice had no overt cardiac phenotype at
baseline; however, in response to pressure overload, car-
diomyocyte hypertrophy was augmented compared to
wild-type mice. No apparent differences in cardiac func-
tion were observed between wild-type and RASSF1A KO
mice. Interestingly, cardiac fibrosis was enhanced in
RASSF1A KO mice following pressure overload [136,137].
Further comparison between systemic RASSF1A KO mice
and cardiac-specific RASSF1A CKO mice revealed a para-
crine mechanism involving TNF-α secretion by cardiac fi-
broblasts that mediated the enhanced growth and fibrosis
observed in RASSF1A KO hearts [137]. Importantly,
RASSF1A CKO mice had better cardiac function after
pressure overload compared to controls, indicating that
RASSF1A function is most likely cell-type-dependent.
RASSF1A was also shown to promote Mst1 activation
both in cultured cardiomyocytes and the mouse heart,
which mediated its pro-apoptotic effect [137]. Therefore,
it appears that RASSF1A is an important upstream regula-
tor of Mst1 in the mammalian heart, but the overall im-
pact of RASSF1A on the myocardium is a balance
between cell-type-specific signaling and interactions.
Yap is an oncogene that can promote tumorigenesis
[39,138-144], yet its function in the adult heart has only
recently been investigated. Systemic deletion of Yap re-
sults in embryonic lethality at day E8.5 [145,146]. Simi-
larly, disruption of Tead1 also causes embryonic death
around E11-12 [138]. Interestingly, Tead1-/- embryos
showed severe cardiac abnormalities including enlarged
pericardial cavities, thin ventricular walls and reduced
number of trabeculae [145]. These findings suggest that
Yap and TEAD1 may have redundant functions during
early embryonic development, one of which may be the
regulation of heart formation in mice. To avoid embryonic
lethality and allow for the study of Yap function in later
stages of development, tissue-specific Yap deletion has
been attained and employed [99]. Myocardial postnatal
deletion of Yap caused a rapid and severe cardiomyopathy
with premature death by 10-12 weeks of age [122,123].
Yap CKO mice had robust increases in cardiomyocyte
apoptosis and cardiac fibrosis that were associated with
decreased cardiac function, indicating a critical role for
Yap in maintaining adult heart homeostasis [122]. TAZ
CKO mice have also been generated [123]. Interestingly,
postnatal cardiac TAZ deletion did not result in an obvi-
ous phenotype and did not appear to alter lifespan. Simi-
larly, hemizygous myocardial Yap deletion (Yap+/-) did
not elicit a baseline cardiac phenotype compared to con-
trol mice [122]. However, following chronic MI stress,
during which Yap is activated at the site of injury, Yap+/-mice showed increased cardiomyocyte apoptosis and fi-
brosis. Furthermore, Yap+/- hearts had significantly fewer
proliferating cardiomyocytes, attenuated cardiomyocyte
compensatory hypertrophy, and worsened heart function
compared to control mice after MI [122]. Conversely,
transgenic expression of activated Yap in mouse hearts, ei-
ther prior to or immediately after MI, protected against
MI-induced injury [123,124]. Increased Yap expression in
adult mouse hearts caused an increase in cardiomyocyte
proliferation and significantly reduced scar formation
[123,124]. These findings are comparable to those ob-
served in Sav1 CKO hearts after MI, a condition that
upregulates Yap activity [125]. Taken altogether, these re-
sults indicate that Yap is required for adult heart homeo-
stasis and is strongly cardioprotective, likely through its
ability to promote both cardiomyocyte survival and prolif-
eration in response to injury.
Exploiting Hippo signaling for heart regeneration
Because Yap activation has been shown to 1) regulate
fetal heart growth [60,61,115], 2) promote cardiomyocyte
proliferation in both neonatal and adult cardiomyocytes
in vivo [115,122-124] and 3) extend the regenerative
capacity of the neonatal mouse heart [123,125], Hippo
signaling has become an intriguing potential target of
manipulation for heart regeneration. However, sizable
challenges exist. Stimulating adult cardiomyocytes to re-
enter the cell cycle and proliferate is a major barrier.
Even a signal as potent as activated Yap expression can-
not drive a subpopulation of adult cardiomyocytes to-
ward division at a rate that is likely to have much
regenerative impact. Indeed, Yap-mediated success in
neonatal cardiomyocytes is much greater, indicating that
fundamental differences emerge with age. Similarly,
stimulating Yap activity through Hippo loss of function
had comparable effects on adult cardiomyocyte prolifer-
ation, raising the question of whether this approach will
be viable and how it might be enhanced. Another con-
cern is the potential for tumorigenesis as a result of in-
creased Yap activation since its oncogenic potential has
been demonstrated in proliferative tissues. Although the
use of stem cells and cardiac progenitor cells for the
treatment of MI in patients has been controversial, this
remains another potential route of exploration for Hippo
manipulation. Yap has been shown to influence stem/
progenitor cell potency and differentiation, yet its func-
tion in adult cardiac progenitors is not known. It is pos-
sible that engineering cardiac progenitors through
modulation of Hippo signaling could afford a more ro-
bust progenitor population and increased therapeutic
benefit. Additionally, the level of Yap expression/activa-
tion in adult cardiac progenitor cells is not known and it
would be interesting to determine whether Yap could
serve as a marker of cardiac progenitors, similar to c-kit,
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overcomes the limitations of those populations being
isolated and used currently [147].
Conclusions
The Hippo signaling pathway has risen to prominence and
is regarded as an important transduction mechanism that
regulates cell growth, proliferation and survival. It has im-
portant implications for physiology and pathology that are
the focus of intense ongoing research. Studies to elucidate
the importance of Hippo signaling in cardiovascular biology
and disease continue to shed light and reveal further com-
plexity of this cascade in the mammalian heart. Future
work may focus on the following points of outstanding
interest: 1) the underlying mechanism explaining how Yap
promotes cardiomyocyte proliferation; 2) upstream regula-
tion of Hippo and how various stresses modulate the path-
way; 3) possible crosstalk between additional established
signaling networks that impact the heart; and 4) targeting
Hippo components using small molecules to influence sig-
naling and outcomes.
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